Recombinant immunotoxins: Protein engineering for cancer therapy

Molecular Medicine Today

Volumn 2, Issue 10, 1996, Pages 439-446

  Brinkman, Ulrich ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIAL TOXIN; EXOTOXIN; GROWTH PROMOTOR; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOTOXIN; IMMUNOTOXIN LMB 7; IMMUNOTOXIN LMB-7; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; LEUKEMIA; LYMPHOMA; METABOLISM; MOUSE; NEOPLASM; PROTEIN ENGINEERING;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; BACTERIAL TOXINS; EXOTOXINS; GROWTH SUBSTANCES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTOXINS; LEUKEMIA; LYMPHOMA; MICE; MODELS, MOLECULAR; NEOPLASMS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; VIRULENCE FACTORS;

EID: 0030255965     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/1357-4310(96)84848-9     Document Type: Review

References (42)

1. Vitetta, E. (1994) From the basic science of B cells to biological missiles at the bedside, J. Immunol. 153, 1407-1420
2. Pastan, I., Chaudhary, V. and FitzGerald, D.J. (1992) Recombinant toxins as novel therapeutic agents, Annu. Rev. Biochem. 61, 331-354
3. Brinkmann, U. and Pastan, I. (1994) Immunotoxins against cancer, Biochim. Biophys. Acta. 1198, 27-45
4. O'Hare, M. et al. (1990) Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically cleavable spacer sequence, FEBS Lett. 273, 200-204
5. Gadina, M. et al. (1994) Humanized immunotoxins, Ther. Immunol. 1, 59-64
6. Allured, V.S., Collier, R.J., Carroll, S.F. and McKay, D.B. (1986) Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Å, Proc. Natl. Acad. Sci. U. S. A. 83, 1320-1324
7. Hwang, J., FitzGerald, D.J., Adhya, S. and Pastan, I. (1987) Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli, Cell 48, 129-136
8. FitzGerald, D. et al. (1994) Selection of pseudomonas exotoxin-resistant cells with altered expression of α2MR/LRP, Ann. New York Acad. Sci. 737, 138-144
9. Chiron, M.F., Fryling, CM. and FitzGerald, D.J. (1994) Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver, J. Biol. Chem. 269, 18167-18176
10. Batra, J.K. et al. (1989) Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of pseudomonas exotoxin, Proc. Natl. Acad. Sci. U. S. A. 86, 8545-8549
11. Pai, L.H. et al. (1991) Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of pseudomonas exotoxin, Proc. Natl. Acad. Sci. U. S. A. 88, 3358-3362
12. Chaudhary, V.K. et al. (1989) A recombinant immunotoxin consisting of two antibody variable domains fused to pseudomonas exotoxin, Nature 339, 394-397
13. Brinkmann, U. et al. (1991) B3(Fv)-PE38KDEL, a single chain immunotoxin that causes complete regression of a human carcinoma in mice, Proc. Natl. Acad. Sci. U. S. A. 88, 8616-8620
14. Batra, J.K. et al. (1992) Recombinant anti-ErbB2 immunotoxins containing pseudomonas exotoxin, Proc. Natl. Acad. Sci. U. S. A. 89, 5867-5871
15. Theuer, C.P., Kreitman, R.J., FitzGerald, D.J. and Pastan, I. (1993) Immunotoxins made with a recombinant form of pseudomonas exotoxin A that do not require proteolysis for activity, Cancer Res. 53, 340-347
16. Y immunotoxin not requiring proteolytic activation, Proc. Natl. Acad. Sci. U. S. A. 93, 974-978
17. Brinkmann, U. and Pastan, I. (1995) Recombinant immunotoxins: from basic research to cancer therapy, Methods Companion Methods Enzymol. 8, 143-158
18. Glockshuber, R., Malia, M., Pfitzinger, I. and Pluckthun, A. (1990) A comparison of strategies to stabilize immunoglobulin Fv-fragments, Biochemistry 29, 1362-1367
19. Huston, J.S. et al. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analog produced in Escherichia coli, Proc. Natl. Acad. Sci. U. S. A. 85, 5879-5883
20. Bird, R.E. et al. (1988) Single-chain antigen binding proteins, Science 242, 423-426
21. Brinkmann, U. et al. (1993) A recombinant immunotoxin containing a disulfide-stabilized Fv fragment, Proc. Natl. Acad. Sci. U. S. A. 90, 7538-7542
22. Reiter, Y. et al. (1994) Improved binding and antitumor activity of a recombinant anti-ErbB2 immunotoxin by disulfide stabilization of the Fv fragment, J. Biol. Chem. 269, 18327-18331
23. Brinkmann, U., Buchner, J. and Pastan, I. (1992) Independent domain folding of pseudomonas exotoxin and single-chain immunotoxins: influence of inter-domain connections, Proc. Natl. Acad. Sci. U. S. A. 89, 3075-3079
24. Buchner, J., Pastan, I. and Brinkmann, U. (1992) A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies, Anal. Biochem. 205, 263-270
25. Kreitman, R. and Pastan, I. (1994) Recombinant single-chain immunotoxins against T and B cell leukemias, Leukemia Lymphoma 13, 1-10
26. Kreitman, R. and Pastan, I. (1995) Targeting pseudomonas exotoxin to hematologic malignancies, Semin. Cancer Biol. 6, 297-306
27. Murphy, J.R. and VanderSpek, J.C. (1995) Targeting diphtheria toxin to growth factor receptors, Semin. Cancer Biol. 6, 259-267
28. Siegall, C. et al. ( 1994) In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats, J. Immunol. 152, 2377-2384
29. Pastan, I., Pai, L., Brinkmann, U. and FitzGerald, D. (1995) Recombinant toxins: new therapeutic agents for cancer, Ann. New York Acad. Sci. 758, 345-354
30. Pastan, I., Pai, L., Brinkmann, U. and FitzGerald, D. (1996) Recombinant immunotoxins, Breast Cancer Res. Treat. 38, 3-9
31. Pai, L. and Pastan, I. (1994) Immunotoxins and recombinant toxins for cancer treatment, in Important Advances in Oncology (DeVita, V., Hellman, S. and Rosenberg, S., eds), pp. 3-19, J.B. Lippincott
32. Pai, L.H. and Pastan, I. (1993) The use of immunotoxins for cancer therapy, Eur. J. Cancer 11, 1606-1609
33. Pai, L.H. and Pastan, I. (1993) Immunotoxin therapy for cancer, J. Am. Med. Assoc. 269, 78-81
34. Benhar, I. and Pastan, I. (1994) Cloning, expression and characterization of the Fv fragments of the anticarbohydrate monoclonal antibodies B1 and B5 as single-chain immunotoxins, Protein Eng. 7, 1509-1515
35. Reiter, Y. et al. (1994) Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment, Cancer Res. 54, 2714-2718
36. Benhar, I., Reiter, Y., Pai, L.H. and Pastan, I. (1995) Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice, Int. J. Cancer 62, 351-355
37. Pastan, I. et al. (1995) Intrathecal administration of single-chain immunotoxin, LMB-7 (B3(Fv)-PE38), produces cures of carcinomatous meningitis in a rat model, Proc. Natl. Acad. Sci. U. S. A. 92, 2765-2769
38. Pai, L.H. et al. (1996) Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to pseudomonas exotoxin, Nat. Med. 1, 350-353
39. Gould, B.J. et al (1989) Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies, J. Natl. Cancer Inst. 81, 775-781
40. Pastan, I. et al. (1991) Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas, Cancer Res. 51, 3781-3787
41. Buchner, J. and Rudolph, R. (1991) Routes to active proteins from transformed microorganisms, Curr. Opin. Biotechnol. 2, 532-538
42. Wels, W. et al. (1992) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the ErbB-2 receptor, Cancer Res. 52, 6310-6317